Quarterly Report III 15/16
September 2015 – May 2016, Diamyd Medical AB (publ), Fiscal year 2015/2016
Reporting period, Mar 1, 2016 – May 31, 2016
- Net result amounted to MSEK -18.2 (-7.3), of which impairment of holding in associated company amounted to MSEK -13.5 (0)
- Net result per share amounted to SEK -0.8 (-0.3)
- Cash flow from operating activities amounted to MSEK -4.3 (-4.8)
- Liquid assets and short term investments amounted at the end of the period to MSEK 36.5 (34.2)
September 1, 2015 – May 31, 2016
- Net result amounted to MSEK -27.2 (-17.2), of which impairment of holding in associated company amounted to MSEK -13.5 (0)
- Net result per share amounted to SEK -1.0 (-0.7)
- Cash flow from operating activities amounted to MSEK -13.7 (-14.6)
Significant events during the reporting period
- Diamyd® in combination with etanercept and vitamin D shows safety in a first preliminary interim report
- Study where Diamyd® is administered directly into lymph nodes, DIAGNODE-1, is approved for expansion and inclusion of children from 12 years of age. Interim results indicate clear and desired re-balancing of the immune system
- Diamyd Medical is engaged in discussions regarding an extension of GABA/Diamyd® trial in Birmingham, Alabama
- Diamyd Medical appoints new CEO who also buys shares in the Company
- Diamyd Medical increases investment in the stem cell company Cellaviva
Significant events after the reporting period
- The associated company Cellaviva withdraws new share issue. Diamyd Medical makes an impairment of its previous holding of MSEK 13.5. Cellaviva is refinanced and intends to increase its focus on the development of therapeutic stem cell products
It was with great pride and humility that I took over the role of CEO of Diamyd Medical nearly two months ago. This has been an intense period and I recently returned from the American Diabetes Association’s (ADA) 76th Scientific Sessions in New Orleans, the world’s largest diabetes conference, with more than 16,000 delegates. The principal message for the type 1 diabetes field was clear: combination therapy and innovative studies are the key to preventing and curing the disease. Government players in the US are showing increasing commitment to curing and preventing diabetes and we have also seen at other conferences we attended earlier in the spring a clear and intensified interest in Diamyd Medical from regional pharmaceutical companies. This is extremely positive for Diamyd Medical. With six ongoing researcher-initiated phase II studies, in which the diabetes vaccine Diamyd® is combined with other substances, we are ahead of our time. During the period, we reported that the innovative open DIAGNODE study, led by Professor Johnny Ludvigsson at Linköping University, demonstrated good safety and promising immunological responses in a first preliminary interim evaluation of data from four patients in the study. It is the first study of its kind in which the concept of intralymphatic administration of an antigen is used in an autoimmune disease, a concept that has been demonstrated to be highly effective in the allergy field. We had a rewarding meeting with the Swedish Medical Products Agency regarding a potential Diamyd® and GABA study that is being planned together with Professor Per-Ola Carlsson at Uppsala University Hospital, and there is interest in further studies among researchers around the world. Discussions are also in progress regarding a possible extension of the ongoing and highly interesting Diamyd® and GABA combination study at the University of Alabama at Birmingham, USA.
Regarding Diamyd Medical’s holdings, it is positive that Cellaviva has received MSEK 8 in refinancing and that the operation is being broadened as a result of a new department being created within Cellaviva for development of stem cells for immunomodulating and regenerative medicine. Diamyd Medical’s shareholding is reduced from approximately 45% to approximately 22%. For the sake of clarity, Diamyd Medical has chosen to impair the previous value of the holding in its entirety. As far as our other holdings are concerned, at ADA I met Sean Saint who is President of Companion Medical, in which Diamyd Medical owns 8.5% of the shares. Companion is developing an insulin pen that is linked to a smartphone application, and its 510k application to the FDA is on schedule.
Recently published articles and conference abstracts on ADA strengthen GAD’s and GABA’s key roles in diabetes. In the journal Diabetes (Phelps et al.), new research shows that an immunogenic variant of GAD in type 1 diabetes accumulates in damaged or stressed beta cells, with the hypothesis that this is the cause of the autoimmune disease. An abstract by Professor Qinghua Wang of the University of Toronto and also a member of our Scientific Advisory Board, shows that in an animal model GABA increases the metabolism in fatty tissue. Earlier studies have demonstrated GABA’s anti-inflammatory effects and function as a neurotransmitter substance in the pancreas, where it promotes the production of insulin, inhibits glucagon secretion and has potentially favorable effects on beta cell survival and growth. There is continued strong interest in further development involving Diamyd Medical’s patented substances in the type 1 diabetes field and new research findings are also opening the way for GABA as a potential component in the treatment of, for example, type 2 diabetes.
I am convinced that Diamyd Medical is at the very leading edge of the type 1 diabetes field, with clinical studies that are in line with what leading experts see as the future of this area. Out-licensing is top of the agenda. We have excellent relations with large pharmaceutical companies and, as mentioned above, there is clear interest from regional pharmaceutical companies. My task as CEO is to refine the strengths and core assets of the company and capitalize on the fact that we have the wind in our sails to ensure that Diamyd Medical grows and becomes a profitable diabetes company, with clarity in how we relate to our cooperative partners and to you, our shareholders. And most important of all, we will do our utmost to prevent and cure type 1 diabetes, one of the most serious diseases that is affecting increasing numbers of children in the world.
Stockholm, June 29, 2016
President and CEO of Diamyd Medical AB (publ)
Significant events during the reporting period
Diamyd® in combination with etanercept and vitamin D shows safety in a first preliminary interim report
A first six-month interim report comprising five patients in EDCR IIa, a pilot researcher-initiated clinical study in which the diabetes vaccine Diamyd® is combined with two other already approved agents, the immunosuppressive drug etanercept and vitamin D, preliminary shows the treatment is safe and tolerable. No serious side effects have been reported. This is the first time that this combination of agents is tested against the complex autoimmune process that causes type 1 diabetes.
Study where Diamyd® is administered directly into lymph nodes, DIAGNODE-1, is approved for expansion and inclusion of children from 12 years of age. Interim results indicate clear and desired re-balancing of the immune system
DIAGNODE-1, an open-label clinical pilot study in which the diabetes vaccine Diamyd® is administered directly into lymph nodes, has been approved by the Swedish Medical Products Agency and the Ethics Review Board to be expanded from five to nine patients and to include children from 12 years of age. Professor Johnny Ludvigsson presents preliminary evaluation of data from the first four patients in the study at the diabetes meeting SSSD in Reykjavik on April 21-22, 2016. The interim results indicate that administration of a low dose of the diabetes vaccine Diamyd® in lymph glands clearly re-balances the immune system towards a desired so called Th2 response. As previously reported, the treatment appears to be safe and tolerable and the clinical progression seems positive.
Diamyd Medical is engaged in discussions regarding an extension of GABA/Diamyd® trial in Birmingham, Alabama
Diamyd Medical is engaged in discussions regarding an extension of the ongoing GABA/Diamyd® trial in Birmingham, Alabama. The Company also announced that the associated company Companion Medical, Inc. has submitted a 510(k) Premarket Notification in the US as well as a CE-mark application in Europe.
Diamyd Medical appoints new CEO who also buys shares in the Company
Ulf Hannelius (40), PhD in molecular biology from Karolinska Institute and with an MBA from Stockholm School of Economics is appointed to, and assumes as of April 11, the position as CEO of Diamyd Medical. Ulf Hannelius buys 20,000 B-shares in Diamyd Medical.
Diamyd Medical increases investment in the stem cell company Cellaviva
Within the framework of a convertible loan of SEK 2.7 million mainly directed at existing shareholders, Diamyd Medical increases its investment in the associated company Cellaviva AB with an additional MSEK 1.3.
Significant events after the reporting period
Diamyd Medical’s associated company Cellaviva withdraws new share issue. Diamyd Medical makes an impairment of its previous shareholding. Cellaviva is refinanced and intends to increase its focus on the development of therapeutic stem cell products
Diamyd Medical’s associated company Cellaviva withdraws a new share issue due to low participation in the issue. Cellaviva is refinanced by approximately MSEK 8.2 through the exercise of a convertible loan of about MSEK 2.7 and a capital contribution of approximately MSEK 5.5, of which Diamyd Medical’s shares amount to MSEK 1.3 and MSEK 1, respectively. Cellaviva intends to increase its focus on the development of therapeutic stem cell products. Diamyd Medical announces concurrently in its quarterly report that an impairment is made of the previous holding of approximately MSEK 13.5.
*** To read the complete report, please visit www.diamyd.com, or see attached PDF ***
For more information, please contact:
Ulf Hannelius, President and CEO, phone: +46 736 35 42 41
Diamyd Medical AB (publ), Kungsgatan 29, SE-111 56 Stockholm, Sweden
Phone: +46 8 661 00 26 Fax: +46 8 661 63 68 E-mail: firstname.lastname@example.org Reg. no: 556242-3797
Note: This document has been prepared in both Swedish and English. The Swedish version shall govern in case of differences between the two documents. The document contains certain statements about the Company’s operating environment and future performance. These statements should only be regarded as reflective of prevailing interpretations. No guarantees can be made that these statements are free from errors.